Sequential high-recovery nanofiltration and electrochemical degradation for the treatment of pharmaceutical wastewater.

The presence of antibiotics in aquatic ecosystems poses a significant concern for public health and aquatic life, owing to their contribution to the proliferation of antibiotic-resistant bacteria. Effective wastewater treatment strategies are needed to ensure that discharges from pharmaceutical manufacturing facilities are adequately controlled. Here we propose the sequential use of nanofiltration (NF) for concentrating a real pharmaceutical effluent derived from azithromycin production, followed by electrochemical oxidation for thorough removal of pharmaceutical compounds. The NF membrane demonstrated its capability to concentrate wastewater at a high recovery value of 95 % and 99.7 ± 0.2 % rejection to azithromycin. The subsequent electrochemical oxidation process completely degraded azithromycin in the concentrate within 30 min and reduced total organic carbon by 95 % in 180 min. Such integrated treatment approach minimized the electrochemically-treated volume through a low-energy membrane approach and enhanced mass transfer towards the electrodes, therefore driving the process toward zero-liquid-discharge objectives. Overall, our integrated approach holds promises for cost-effective and sustainable removal of trace pharmaceutical compounds and other organics in pharmaceutical wastewater.

Superoleophilic conjugated microporous polymer nano-surfactants for realizing unprecedented fast recovery of volatile organic compounds.

A pervaporation membrane with fast and selective permeation is key to improving the recovery efficiency of volatile organic compounds from water. Here, we synthesize a new type of nanofiller-conjugated microporous polymer (CMP) to fabricate polydimethylsiloxane (PDMS)-based mixed matrix membranes (MMMs) and explore their application in the recovery of organic solvents from water via pervaporation. Due to their good dispersibility in the dope solvent and compatibility with PDMS, uniform MMMs without discrete particle phases or aggregates are prepared. Interestingly, CMP nanosheets play a unique role as a nano-surfactant in enhancing both the sorption and diffusion coefficients, realizing unprecedented fast recovery of organic solvents from water. The total flux of the as-fabricated membranes can be enhanced from 74.8 to 406.2 kg µm-2 h-1 and the separation factor αethyl acetate/water is increased from 118.7 to 526.6 when using 5 wt% ethyl acetate aqueous solution as the feed at 50 °C. In addition, the CMP-incorporated PDMS membranes are also effective in recovering a wide range of organic compounds from water, including ethanol, acetone, tetrahydrofuran and acetonitrile.

Anti-gout activity and the interaction mechanisms between Sanghuangporus vaninii active components and xanthine oxidase.

Xanthine oxidase (XO) plays a critical role in the progression of gout. We showed in a previous study that Sanghuangporus vaninii (S. vaninii), a perennial, medicinal, and edible fungus traditionally used to treat various symptoms, contains XO inhibitors. In the current study, we isolated an active component of S. vaninii using high performance countercurrent chromatography and identified it as davallialactone using mass spectrometry with 97.726 % purity. A microplate reader showed that davallialactone had mixed inhibition of XO activity with a half-inhibitory concentration value of 90.07 ± 2.12 µM. In addition, the collision between davallialactone and XO led to fluorescence quenching and conformational changes in XO, which were mainly driven by hydrophobicity and hydrogen bonding. Molecular simulations further showed that davallialactone was located at the center of the molybdopterin (Mo-Pt) of XO and interacted with amino acid residues Phe798, Arg912, Met1038, Ala1078, Ala1079, Gln1194, and Gly1260, suggesting that entering the enzyme-catalyzed reaction was unfavorable for the substrate. We also observed face-to-face π-π interactions between the aryl ring of davallialactone and Phe914. Cell biology experiments indicated that davallialactone reduced the expression of the inflammatory factors, tumor necrosis factor alpha and interleukin-1 beta (P < 0.05), can effectively alleviate cellular oxidative stress. This study showed that davallialactone significantly inhibits XO and has the potential to be developed into a novel medicine to prevent hyperuricemia and treat gout.